Betalactam Antibiotics and LRTI
description
Transcript of Betalactam Antibiotics and LRTI
![Page 1: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/1.jpg)
Betalactam Antibiotics and LRTI
Oğuz KılınçDokuz Eylul University School of Medicine
Chest [email protected]
![Page 2: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/2.jpg)
Conflict of Interest(Last 3 years)
• Congress sponsorship– Abdi İbrahim– Actavis– Boehringer İngelheim– Chiesi– GSK– Novartis– Pfizer
• Advisory Board– Bayer– Boehringer İngelheim– Chiesi– GSK– Novartis– Pfizer
• Lecturer Fee– Astra– Bayer– Boehringer İngelheim– GSK– Novartis– Pfizer
• Clnical Research Support– Astra– Bayer– GSK– Novartis– Pfizer
• Tütün endüstrisiyle hiçbir ilişkim yoktur.
![Page 3: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/3.jpg)
Lecture Plan
• What is LRTI?• Caracteristics of betalactam antibiotics• Betalactam antibiotics and LRTI?
![Page 4: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/4.jpg)
What is LRTI?
• CAP• AECOPD• AE of bronchiectasis• Acute bronchitis
• M Woodhead. Clin Microbiol Infect 2011; 17(Suppl. 6): E1–E59
![Page 5: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/5.jpg)
Betalactam antibiotics
– Penicillin– Cephalosporins– Carbapenems– Monobactams– Betalactamase inhibitors
http://yunus.hacettepe.edu.tr/~pkelicen erişim tarihi 18.03.2012
![Page 6: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/6.jpg)
BetalactamsSubclasses Prototype Major Variants
Penicillins Limited spectrum Penicillin G Penicillin V
Betalactamase resistant
Methicillin Nafcillin, oxacillin Cloaxacillin
Wider spectrum Ampicillin, Carbenicillin Amoxacillin, ticarcillin
Cephalosporins 1. generation Sodium sefhalotin Cefazolin,Cephradin,
Cephapirin
2. generation Cefamandole Cefaclor, cephatetan, cephoxitin
3. generation Cefaperazone Cefotaxim, Ceftazidim, Ceftriaxon
Carbapenem İmipenem
Monobactam Aztreonam
Betalactamase inhibitors * Clavulanic asit Sulbactam, Tazobactam
* Negligible antimicrobial activity when given alonehttp://yunus.hacettepe.edu.tr/~pkelicen downloded 18.03.2012
![Page 7: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/7.jpg)
Betalactams
http://yunus.hacettepe.edu.tr/~pkelicen erişim tarihi 18.03.2012
![Page 8: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/8.jpg)
Betalactams
http://yunus.hacettepe.edu.tr/~pkelicen erişim tarihi 18.03.2012
![Page 9: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/9.jpg)
Resistans mechanism to penicillins
• Inactivation of betalactam body because of betalactamase – Betalactamase secretion to periplasmic space
(S. aureus ve Gram (-) )– Out of membrane (Gram (+))
• Decrase of PBP affinity • Decrase of cell wall permiability
Kayaalp O. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji, 10. Baskı, Hacettepe Taş, 2002.
![Page 10: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/10.jpg)
Clinical caracteristics of cephalosporins
• A part of patients who have penicilline allergy,• Betalactamase (+) S. aureus infections • PBP
Kayaalp O. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji, 10. Baskı, Hacettepe Taş, 2002.
![Page 11: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/11.jpg)
Carbapenems
• High affinty to PBP 1 and 2• Resistant to betalaktamase• Bacterisid for betalactam resistans bacteria
Kayaalp O. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji, 10. Baskı, Hacettepe Taş, 2002.
![Page 12: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/12.jpg)
![Page 13: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/13.jpg)
Aetiology of LRTI in the community
![Page 14: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/14.jpg)
Aetiology of CAP(Outpatient)
![Page 15: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/15.jpg)
![Page 16: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/16.jpg)
![Page 17: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/17.jpg)
![Page 18: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/18.jpg)
![Page 19: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/19.jpg)
![Page 20: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/20.jpg)
Betalactamase resistans in Turkey?S. pneumoniae
• EARSS (2008)• 32 European country (Turkey data) invasiv S.
pneumonia • PNSP %34
![Page 21: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/21.jpg)
![Page 22: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/22.jpg)
S. pneumoniae Penicilline resistans- effect of therapy?
• PO treatment– MIC • Sensitive (≤ 0.06 mg/L), intermediate (0.12- 1 mg/L),
resistans ( ≥2 mg/L)
• Parenteral treatment– Sensitive (≤ 2 mg/L), intermediate (4 mg/L),
resistans ( ≥8 mg/L)– Good news for clinicans
![Page 23: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/23.jpg)
Pneumococci resistans in Turkey
Gülmez D ve ark. ECCMID Congress 2010
![Page 24: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/24.jpg)
H. influenzae betalactam resistans
• EARSS study• Main resistans mechanism beta-laktamase
production (mean %7.6)• Cephalosporin and betalactamase inhibitor +
betalactam
• PBP 3 coding gen (BLNAR)• Resistans to aminopenicilline and cephalosporine
![Page 25: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/25.jpg)
M. catarrhalis –betalactam resistans
• No change since 1999 .• All species resistans to ampicillin,
amoxacilline, piperacilline and penicilline • BRO-1, BRO- 2 type betalaktamase resistans• betalactam betalactamase inhibitor.
![Page 26: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/26.jpg)
M. pneumoniae- betalactam resistans
• Resistans to all betalactams
![Page 27: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/27.jpg)
CA- MRSA
• Resistans to all betalactams
![Page 28: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/28.jpg)
Treatment
• Penicilline G 3.2 M U x 6 IV• Ceftriaxone 1g x 2 IV/IM• Cefotaxime 2g x 4 IV
• Amoxacilline+clavulanic acid 2g/125mg x 2 PO
![Page 29: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/29.jpg)
• Double blind, randomized controlled, monoterapy study meta-analysis
• 18 study, 6749 patients• Mild and moderate CAP
Mills GD ve ark. BMJ 2005
![Page 30: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/30.jpg)
Mills GD ve ark.BMJ 2005
![Page 31: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/31.jpg)
TTS CAP guideline
• Grup 1– 1A
• Amoksisilin veya Makrolid– 1B
• 2.3. kuşak oral sefalosporin veya KAM +/- Makrolid/Doksisiklin• Grup 2
• 3. kuşak antipseudomonas olmayan sefalosporin veya betalaktam+ betalaktamaz inhibitörlü aminopenisilin + Makrolid /quinolon
• Grup 3– 3A
• 3 generation non- pseudomonas cephalosporin or betalactam+ betalactamase inhibitor + Macrolid or quinolon
– 3B• Antipseudomonas betalactam+ciprofloksasin or aminoglikozid + Macrolid
![Page 32: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/32.jpg)
Wrap up
• We have to know what we treat• Surveillance of resistans rate• Appropiate treatment
![Page 33: Betalactam Antibiotics and LRTI](https://reader031.fdocuments.net/reader031/viewer/2022020102/5681465e550346895db37ed6/html5/thumbnails/33.jpg)
Teşekkürler